IQVIA Holdings (IQV) Earnings Date & Reports

IQVIA's Q1 2026 revenue totaled $4,151 million, exceeding consensus estimates of approximately $4.10 billion and growing 8.4% year-over-year (6.0% at constant currency). The company reported GAAP net income of $274 million, or $1.61 diluted EPS. Adjusted diluted EPS was $2.90, topping expectations of $2.83 and up 7.4% from $2.70 in Q1 2025.

Segment performance shone: Commercial Solutions revenue rose 11.6% (8.5% constant currency) to $1,754 million, fueled by patient solutions, analytics, and AI tools. R&DS revenue increased 6.2% (4.2% constant currency) to $2,397 million, or 6.6% excluding pass-through costs. Adjusted EBITDA hit $932 million, up 5.5%.

Guidance updates included reaffirmed full-year revenue of $17.15-$17.35 billion and Adjusted EBITDA of $3.975-$4.025 billion, with adjusted diluted EPS raised to $12.65-$12.95. R&DS backlog stood at $34.2 billion (book-to-bill 1.04x), signaling steady pipeline conversion.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your stock discovery process.

Market Reaction and Investor Sentiment

Despite beating top- and bottom-line estimates, IQV shares initially dipped in pre-market trading by around 5% to near $153, reflecting caution over broader market dynamics and prior YTD declines. However, sentiment shifted positively during the day, with the stock rallying over 9% to close around $176, driven by the raised EPS guidance and robust backlog. Investors interpreted the results as validation of accelerating organic growth and AI traction, though some noted R&DS stabilization rather than acceleration.

Forward Outlook and Key Factors to Monitor

IQVIA's raised full-year adjusted EPS guidance to $12.65-$12.95 signals confidence in margin expansion and cash generation, supported by $552 million in Q1 share repurchases (remaining authorization: $1.217 billion). Free cash flow conversion at 100% of adjusted net income underscores operational strength.

Key to watch: R&DS net new bookings ($2.5 billion in Q1, book-to-bill 1.04x) and backlog conversion (~$8.9 billion over next 12 months). Stabilizing clinical trial demand, with mid-to-high single-digit growth in forward indicators, could drive upside if biopharma R&D budgets rebound.

In Commercial Solutions, monitor AI-enabled offerings' adoption in analytics and patient engagement, which fueled double-digit growth. Broader factors include foreign exchange tailwinds (~100 bps for FY2026), acquisition contributions (~150 bps), and interest rate impacts on debt costs.

Upcoming catalysts: Q2 results in July, potential M&A (mergers and acquisitions (M&A)) activity, and industry trends like real-world evidence demand. Balanced execution here will shape trajectory amid life sciences sector volatility.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations